VLP Therapeutics names seasoned biotech venture capitalist Miwa Toyoda as CBO

2021-03-14T11:28:14-04:002021.03.15|

Gaithersburg, MD — US-based biotech company VLP Therapeutics, Inc. (VLPT) announced that it has named Ms. Miwa Toyoda, formerly a venture capitalist specialized in pharma and biotech at JAFCO Group Co., Ltd., as chief business officer, effective March 15, in a bid to accelerate its vaccine research and development projects and expand the portfolio. From

VLP Therapeutics raises $16M Series A for cancer treatment vaccine R&D

2021-03-25T21:15:43-04:002021.03.15|

Gaithersburg, MD — US-based biotech company VLP Therapeutics, Inc. (VLPT) announced on March 15 that it has raised US$16 million in a Series A funding round from MIYAKO Capital Co., Ltd., Sojitz Corporation, Konishiyasu Co., Ltd. in Japan, and three existing investors in the US (Mr. Robert G. Hisaoka, SK Impact Fund, LLC, and RJ

VLP Therapeutics Japan, FUJIFILM sign contract manufacturing agreement for COVID-19 vaccine

2020-10-01T08:04:54-04:002020.10.01|

October 1, 2020 — VLP Therapeutics Japan, LLC (VLPTJ) announced on today that VLPTJ signed a contract manufacturing agreement with FUJIFILM Corporation (FUJIFILM) for a novel coronavirus (COVID-19) vaccine formulation developed by VLPTJ. This self-amplifying (replicon) RNA vaccine employs a platform technology proprietary to VLP Therapeutics, LLC, the US-based wholly owning parent company of VLPTJ.

VLP Therapeutics Japan, a wholly owned subsidiary of VLP Therapeutics, has been selected by the Japanese government AMED fund for development of a protective vaccine against the new coronavirus infectious disease (COVID-19)

2020-08-31T09:57:50-04:002020.08.31|

August 31, 2020   Gaithersburg, MD – VLP Therapeutics announced today that VLP Therapeutics Japan (VLPTJ), a wholly owned subsidiary of VLP Therapeutics, has been selected to receive Japanese government funding through the AMED Fund for the development of a vaccine against the new coronavirus infectious disease (COVID-19)".   VLPTJ applied for this funding in

VLP Therapeutics Receives FDA Clearance of Investigational New Drug Application and Initiates First Clinical Trial of VLPM01 Malaria Vaccine

2019-02-03T23:39:51-05:002019.02.04|

Gaithersburg, MD – VLP Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a clinical trial of the Company’s VLPM01 malaria vaccine. The Phase I/IIa clinical trial has begun recruiting participants in February 2019, and is designed to assess the safety, immunogenicity and efficacy

VLP Therapeutics Awarded $3.9 million Grant by Global Health Innovative Technology Fund for Further Development of Dengue Vaccine

2018-12-12T13:19:44-05:002018.12.12|

December 12, 2018 Gaithersburg, MD - The Global Health Innovative Technology (GHIT) Fund has awarded VLP Therapeutics a $3.9 million grant to further develop a novel tetravalent dengue virus-like particle vaccine. “The GHIT Fund’s commitment is an important step for the further validation of our virus-like particle vaccine technology. We are grateful to the GHIT

Wataru Akahata, Ph.D. Recognized by the Japanese Government as 2018 Significant Researcher

2018-11-29T11:55:47-05:002018.11.29|

November 29, 2018 Dr. Wataru Akahata, CEO and Founder of VLP Therapeutics was  Selected by the Government of Japan as a 2018 Researcher of Significant Contribution to Science  Japan’s National Institute of Science and Technology Policy (NISTEP) and the Japan Ministry of Education, Culture, Sports, Science and Technology (MEXT) (http://www.nistep.go.jp/en/). An announcement by MEXT in

VLP Therapeutics Announces Issuance of US Patent for Dengue Vaccine

2018-10-18T10:17:40-04:002018.10.18|

October 18, 2018 Gaithersburg, MD -- VLP Therapeutics announced the issuance of US Patent 10,098,943 titled, “Flavivirus virus-like particle” on October 16, 2018. This patent supports VLP Therapeutics’ Native Virus Modification virus-like particle platform on which the Company’s dengue vaccine is based and which could form the basis for other flavivirus vaccines. The patent relates

VLP Therapeutics is Recognized by the Government of Japan (Cabinet Office) “Comprehensive Strategy on Science, Technology and Innovation for 2017”

2018-05-29T16:48:33-04:002018.05.29|

VLP Therapeutics was recently recognized as one of eleven companies that exemplify Japan’s commitment to Innovation as outlined in the 2017 Comprehensive Strategy on Science, Technology and Innovation. In 2017 the Cabinet Office of the Government of Japan published a Comprehensive Strategy on Science, Technology and Innovation which outlined a strategy to enhance Japan’s industrial